Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Pharmacyte Biotech Inc. (PMCB:NASDAQ), powered by AI.
Pharmacyte Biotech Inc. is currently trading at $0.83. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Pharmacyte Biotech Inc. on Alpha Lenz.
Pharmacyte Biotech Inc.'s P/E ratio is 0.2.
“Pharmacyte Biotech Inc. trades at a P/E of 0.2 (undervalued) with strong ROE of 67.1%.”
Ask for details →Pharmacyte Biotech Inc. is a biotechnology company focused on the development and commercialization of cellular therapies for cancer and diabetes management. Operating within the burgeoning biotech industry, the company's main objective is to harness leading-edge cellular therapy technologies to offer innovative treatment options. A notable feature of Pharmacyte Biotech Inc. is its proprietary Cell-in-a-Box technology, which is designed for the targeted delivery of chemotherapy drugs to tumor sites, aiming to enhance treatment efficacy while minimizing adverse effects. Furthermore, the company is actively exploring applications of its technology platform for treating diabetes by encapsulating genetically modified cells that can produce insulin. Pharmacyte Biotech Inc.'s advancements are significant in the asset's market, as they represent potential breakthroughs in addressing challenging medical conditions with unmet therapeutic needs. By collaborating with researchers and key players in the medical field, Pharmacyte Biotech Inc. seeks to make a substantial impact on healthcare outcomes through precision medicine and cutting-edge biotechnological solutions.
“Pharmacyte Biotech Inc. trades at a P/E of 0.2 (undervalued) with strong ROE of 67.1%.”
Ask for details →Pharmacyte Biotech Inc. (ticker: PMCB) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 2 employees. Market cap is $6M.
The current price is $0.828 with a P/E ratio of 0.2x and P/B of 0.12x.
ROE is 67.08%.